# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Chronic Myelomonocytic Leukemia

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 1-10 of 72 results.
Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion
Status: Recruiting
Last Changed: May 29, 2020
First Received: Oct 29, 2018
Disease(s): Chronic Myelomonocytic Leukemia, Leukemia
Intervention(s): Ruxolitinib
Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Cleveland Clinic, Cleveland, Ohio, United States
Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)
Status: Recruiting
Last Changed: Jul 07, 2020
First Received: Feb 12, 2020
Disease(s): Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
Intervention(s): MBG453, Azacitidine, Placebo
Locations: Novartis Investigative Site, Woolloongabba, Queensland, Australia
Novartis Investigative Site, Clayton, Victoria, Australia
Novartis Investigative Site, Linz, Austria
Novartis Investigative Site, Brasschaat, Belgium
Novartis Investigative Site, Praha 2, Czech Republic, Czechia
... and 12 other locations.
Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed
Status: Recruiting
Last Changed: Jul 08, 2019
First Received: Oct 17, 2016
Disease(s): Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes
Intervention(s): Atezolizumab, Guadecitabine
Locations: USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
University of Maryland Medical Center, Baltimore, Maryland, United States
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Temple University Hospital, Philadelphia, Pennsylvania, United States
A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)
Status: Not yet recruiting
Last Changed: Jun 19, 2020
First Received: Feb 11, 2020
Disease(s): Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
Intervention(s): Azacitidine, Cusatuzumab
Locations: City of Hope, Duarte, California, United States
VA San Diego Healthcare System - UCSD, San Diego, California, United States
Louisville Oncology Suburban - Norton Cancer Institute, Louisville, Kentucky, United States
Dartmouth Hitchcock, Lebanon, Louisiana, United States
Tulane University School of Medicine, New Orleans, Louisiana, United States
... and 83 other locations.
Tagraxofusp (SL-401) in Patients With CMML or MF
Status: Recruiting
Last Changed: Jun 04, 2020
First Received: Oct 20, 2014
Disease(s): Myelofibrosis, Chronic Myelomonocytic Leukemia
Intervention(s): SL-401
Locations: City of Hope, Duarte, California, United States
University of California, Los Angeles, Los Angeles, California, United States
University of Kansas Cancer Center, Westwood, Kansas, United States
Norton Cancer Institute, Louisville, Kentucky, United States
Mayo Clinic, Rochester, Minnesota, United States
... and 6 other locations.
Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)
Status: Recruiting
Last Changed: Sep 25, 2019
First Received: Sep 14, 2005
Disease(s): Juvenile Myelomonocytic Leukemia
Intervention(s): Stem Cell Transplant, Preparative Regimen
Locations: Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Canakinumab and Anacitidine for the Treatment of Low or Intermediate Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia
Status: Not yet recruiting
Last Changed: May 01, 2020
First Received: Jan 23, 2020
Disease(s): Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic Syndrome
Intervention(s): Canakinumab
Locations: M D Anderson Cancer Center, Houston, Texas, United States
Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations
Status: Not yet recruiting
Last Changed: Jun 01, 2020
First Received: Jun 01, 2020
Disease(s): Chronic Myelomonocytic Leukemia (CMML)
Intervention(s): Cobimetinib
SNS-301 Monotherapy in High Risk MDS and CMML
Status: Not yet recruiting
Last Changed: Mar 17, 2020
First Received: Jan 03, 2020
Disease(s): Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia (CMML)
Intervention(s): SNS-301
TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Refractory Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Status: Not yet recruiting
Last Changed: Mar 06, 2020
First Received: Jan 25, 2019
Disease(s): Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory High Risk Myelodysplastic Syndrome
Intervention(s): UAE Inhibitor TAK-243